Blueprint Medicines
BPMC

$86.43

5.45%

Market Cap: $5.41B

About: Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Employees: 655

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

167% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 8 (+5) [Q2]

105% more call options, than puts

Call options by funds: $287M | Put options by funds: $140M

96% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 26

14% more repeat investments, than reductions

Existing positions increased: 113 | Existing positions reduced: 99

14% more capital invested

Capital invested by funds: $6.27B [Q1] → $7.13B (+$856M) [Q2]

9% more funds holding

Funds holding: 276 [Q1] → 301 (+25) [Q2]

2.41% less ownership

Funds ownership: 108.05% [Q1] → 105.63% (-2.41%) [Q2]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$105

21%

upside

Avg. target

$125

45%

upside

High target

$138

60%

upside

8 analyst ratings

6 positive

75%

2 neutral

25%

0 negative

0%

Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target	54%upside $133	Buy Maintained	5 Aug 2024
Guggenheim Michael Schmitz 33% 1-year accuracy 1 / 3 met price target	60%upside $138	Buy Maintained	2 Aug 2024
Baird Joel Beatty 51% 1-year accuracy 18 / 35 met price target	47%upside $127	Outperform Maintained	2 Aug 2024
Needham Ami Fadia 55% 1-year accuracy 70 / 128 met price target	50%upside $130	Buy Reiterated	1 Aug 2024
Barclays Peter Lawson 29% 1-year accuracy 8 / 28 met price target	21%upside $105	Equal-Weight Maintained	29 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 33 articles about BPMC published over the past 30 days

Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Engaged In Securities Fraud And Shareholder Participation In An Investigation Is Encouraged By The Schall Law Firm

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Possible Securities Law Violations And Investors Are Urged To Join The Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Possible Securities Law Violations And Investors Are Urged To Join The Inquiry

Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Defrauded Shareholders And The Schall Law Firm Wants Those With Losses To Reach Out

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Potential Securities Law Violations And Investors Are Encouraged To Join

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation For Potential Securities Law Violations And Investors Are Encouraged To Join

Blueprint Medicines Corporation May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Defrauded The Public And The Schall Law Firm Seeks Shareholder Participation In An Inquiry

The Schall Law Firm Is Looking Into Whether Blueprint Medicines Corporation Committed Securities Related Improprieties And Investors Should Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Blueprint Medicines Corporation Committed Securities Related Improprieties And Investors Should Reach Out

Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation

LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

$Shareholders Can Now Join The Schall Law Firm In Investigating Securities Related Infractions By Blueprint Medicines Corporation$

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist

LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Blueprint Medicines Corporation's Possible Securities Fraud And Investors Are Invited To Assist

Blueprint Medicines Corporation May Have Violated Securities Regulations And The Schall Law Firm Seeks Shareholders' Help In The Inquiry

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Blueprint Medicines Corporation May Have Violated Securities Regulations And The Schall Law Firm Seeks Shareholders' Help In The Inquiry

Investors Are Encouraged To Contact The Schall Law Firm About An Investigation Into Blueprint Medicines Corporation's Securities Related Impropriety

LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Contact The Schall Law Firm About An Investigation Into Blueprint Medicines Corporation's Securities Related Impropriety

See News Rankings